Showing results (131-140 of 183) with videos related to
Sort By:
Pageof 19
Antiviral Therapy|May 12, 2009
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido, Ignacio Pérez-Valero, Rafael Delgado, et al.Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.The Lancet. HIV|August 6, 2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trialJhon Rojas, Elisa de Lazzari, Eugenia Negredo, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 9, 2026
Natural history of anal HSIL and predictive value of cytology and HPV biomarkers in MSM living with HIV: a prospective cohort studyAna C Silva-Klug, Sònia Paytubi, Loris Trenti, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.Enfermedades Infecciosas Y Microbiologia Clinica|May 7, 2013
[Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders], Daniel Podzamczer Palter, José A Muñoz-Moreno, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 13, 2025
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trialJose M Miro, Ferran Torres, Christian Manzardo, et al.The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.Enfermedades Infecciosas Y Microbiologia Clinica|September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsJuan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.Pageof 19